• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hepatitis C treatment and quality of life - You can't always get what you want, but you might get what you need.

作者信息

Mehta Gautam, Dusheiko Geoffrey

机构信息

UCL Institute for Liver and Digestive Health, UCL Medical School, Royal Free Campus, London NW3 2PF, United Kingdom.

UCL Institute for Liver and Digestive Health, UCL Medical School, Royal Free Campus, London NW3 2PF, United Kingdom.

出版信息

J Hepatol. 2015 Aug;63(2):300-2. doi: 10.1016/j.jhep.2015.05.004. Epub 2015 May 14.

DOI:10.1016/j.jhep.2015.05.004
PMID:25980761
Abstract
摘要

相似文献

1
Hepatitis C treatment and quality of life - You can't always get what you want, but you might get what you need.丙型肝炎治疗与生活质量——你不能总是如愿以偿，但你可能会得到你所需要的。
J Hepatol. 2015 Aug;63(2):300-2. doi: 10.1016/j.jhep.2015.05.004. Epub 2015 May 14.
2
Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.聚乙二醇干扰素α-2a 联合利巴韦林治疗慢性丙型肝炎的病毒学应答预测因素分析
J Hepatol. 2015 Aug;63(2):337-45. doi: 10.1016/j.jhep.2015.03.014. Epub 2015 Mar 17.
3
Clearance of Hepatitis C Virus After Fixed-Dose Combination Ledipasvir/Sofosbuvir in an Adolescent Female With Decompensated Cirrhosis.固定剂量组合药物来迪派韦/索磷布韦治疗失代偿期肝硬化青春期女性后丙型肝炎病毒的清除情况
J Pediatr Gastroenterol Nutr. 2016 Nov;63(5):516-517. doi: 10.1097/MPG.0000000000001278.
4
Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.在肝移植受者中使用来迪派韦索磷布韦且无利巴韦林治疗 HCV 感染。
Aliment Pharmacol Ther. 2017 Jun;45(11):1427-1432. doi: 10.1111/apt.14059. Epub 2017 Apr 6.
5
No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL.没有科学依据将雷迪帕韦/索磷布韦8周的治疗局限于丙型肝炎病毒RNA＜6,000,000 IU/mL的患者。
Hepatology. 2016 Jan;63(1):28-30. doi: 10.1002/hep.28292. Epub 2015 Nov 25.
6
Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.在慢性丙型肝炎病毒 1 型感染患者中使用雷迪帕韦/索磷布韦联合或不联合利巴韦林的疗效和安全性：一项荟萃分析。
Int J Infect Dis. 2017 Feb;55:56-71. doi: 10.1016/j.ijid.2016.12.023. Epub 2016 Dec 29.
7
Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.来迪派韦-索磷布韦：用于慢性丙型肝炎病毒感染的无干扰素/利巴韦林治疗方案。
Ann Pharmacother. 2015 Mar;49(3):343-50. doi: 10.1177/1060028014563952. Epub 2014 Dec 16.
8
Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus.来迪派韦/索磷布韦固定剂量复方片剂用于台湾慢性基因1型丙型肝炎病毒患者。
J Gastroenterol Hepatol. 2016 Jul;31(7):1323-9. doi: 10.1111/jgh.13305.
9
The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.来迪派韦索磷布韦治疗 12-17 岁 1 型丙型肝炎病毒感染青少年的安全性和有效性。
Hepatology. 2017 Aug;66(2):371-378. doi: 10.1002/hep.28995. Epub 2017 Jun 19.
10
Seronegative Chronic Hepatitis C Virus Infection: A Teachable Moment.
JAMA Intern Med. 2021 Nov 1;181(11):1501-1502. doi: 10.1001/jamainternmed.2021.5182.

引用本文的文献

1
Quality of life, risk behaviors and depression among carriers of hepatitis C virus and human T-cell lymphotropic virus type 1: a comparative study.丙型肝炎病毒和人类 T 细胞嗜淋巴细胞病毒 1 携带者的生活质量、风险行为和抑郁：一项对比研究。
Braz J Infect Dis. 2019 Jul-Aug;23(4):224-230. doi: 10.1016/j.bjid.2019.06.013. Epub 2019 Jul 22.
2
The combined polymorphisms of interleukin-6-174GG genotype and interleukin-10 ATA haplotype are associated with a poor quality of life in patients with chronic hepatitis C.白细胞介素-6-174GG 基因型和白细胞介素-10ATA 单倍型的联合多态性与慢性丙型肝炎患者的生活质量较差相关。
Qual Life Res. 2019 Jun;28(6):1531-1542. doi: 10.1007/s11136-019-02129-5. Epub 2019 Feb 7.